atorvastatin + aspirin + losartan + amlodipine

This drug is a **fixed-dose combination** of four pharmaceutical agents: atorvastatin, aspirin, losartan, and amlodipine. It targets multiple cardiovascular risk factors by combining the following mechanisms: - **Atorvastatin** is a statin (HMG-CoA reductase inhibitor) that lowers cholesterol by inhibiting hepatic cholesterol synthesis, reducing LDL cholesterol, and thereby decreasing atherosclerotic risk. - **Aspirin** is an antiplatelet agent that irreversibly inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A2 production, and thus platelet aggregation, which lowers the risk of thrombotic cardiovascular events. - **Losartan** is an angiotensin II receptor blocker (ARB) that inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, resulting in vasodilation and lowering blood pressure. - **Amlodipine** is a calcium channel blocker (dihydropyridine type) that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, resulting in arterial vasodilation and reduced blood pressure. This combination is intended for patients at risk of or with established cardiovascular disease, especially those with hypertension, dyslipidemia, and a need for antiplatelet therapy. The use of fixed-dose combinations may improve patient adherence and clinical outcomes in cardiovascular prevention.